Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Recruiting · NCT05640102
Conditions: Waldenstrom Macroglobulinemia
At a glance
- Research payments reported, 2025
- $180,482
- U.S. investigators named
- 16
- Sites paid
- 14
- Planned or actual enrollment
- 111
About the trial
- Sponsor
- BeiGene
- Tested
- Zanubrutinib (drug)
- Dates
- Started 2023-03-03; completion 2027-12
- Results posted
- Not yet
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
From ClinicalTrials.gov, last updated 2026-08-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $180,482 in research payments for this study in 2025 (62 payments).
Products named: Brukinsa
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lakshmikanth Katragadda, M.D. Hematology & Oncology · Huntsville, AL
- Delshad Ahmad, MD Hematology & Oncology · Rancho Mirage, CA
- Gorgun Akpek, M.D., M.H.S. Hematology & Oncology · San Luis Obispo, CA
- Wei Bai, MD Hematology & Oncology · Santa Maria, CA
- Constantin Dasanu, M.D., PH.D. Hematology & Oncology · Rancho Mirage, CA
- Eric A. Lee, MD Internal Medicine · Los Angeles, CA
- Geoffrey Shouse, D.O., PH.D. Hematology · Duarte, CA
- Omar Alkharabsheh, MD Hematology & Oncology · Orlando, FL
- Jason Tache, D.O. Hematology & Oncology · Plantation, FL
- Nakhle S. Saba, MD Hematology & Oncology · Baton Rouge, LA
- John S. Hrom, MD Hematology & Oncology · Hattiesburg, MS
- Charles M. Farber, M.D, PHD Hematology & Oncology · Morristown, NJ
- Edwin C. Kingsley, MD Hematology & Oncology · Las Vegas, NV
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Josselyn G. Molina Avila, M.D. Hematology & Oncology · Fajardo, PR
- Adelba Torres-lopez, M.D. Hematology & Oncology · San Juan, PR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- St Josephs Hospital and Medical Center, AZ $45,022
- Clearview Cancer Institute (cci) $23,996
- Tulane Cancer Center $22,678
- Auxilio Mutuo Hospital, PR $22,000
- Comprehensive Cancer Centers of Nevada - Central Valley $13,510
- City of Hope National Medical Ctr $11,129
- Eisenhower Medical Center, CA $10,776
- Pan American Oncology Trials, LLC $7,562
- Brcr Medical Center Inc. $7,260
- Hattiesburg Hematology and Oncology Clinic $6,485
- South Alabama Medical Science Foundation $4,477
- Clinical Research Alliance, Inc. $2,500
- Morristown Medical Center, NJ $1,909
- ?los Angeles Hematology/oncology Medical Group Los Angeles Cancer Network Research $1,178
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.